Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Regorafenib a promising treatment for metastatic colorectal cancer

Tristan Manalac
26 Nov 2017

Regorafenib appears to have promising efficacy as a third- or fourth-line treatment for patients with metastatic colorectal cancer (mCRC), according to a new study from Macau presented at the recently concluded European Society for Medical Oncology Asia 2017 Congress (ESMO Asia 2017).

The research team performed a retrospective review of the medical records of 36 mCRC patients (median age 58 years; 53 percent male) who received regorafenib monotherapy. All participants had prior palliative chemotherapy treatment regimens containing oxaliplatin, irinotecan and fluorouracil with biologics such as bevacizumab or cetuximab.

Majority of the patients were administered regorafenib at 160 mg/day (41 percent), while the others received a daily dose of 120 mg (28 percent) or 80 mg (31 percent).

Of the 36 participants, 45 percent had one to two prior lines of mCRC treatment, 34 percent had three and 21 percent had at least four; 90 percent received prior targeted therapies. Colon cancer was reported in 30, while the remaining 6 had rectal cancer. [ESMO Asia, abstract 152P]

Over a median treatment duration of 4.5 months, 17 patients achieved disease control corresponding to a rate of 47.2 percent.

Compared with those who did not receive the drug, those treated with third- or fourth-line regorafenib had longer median overall survival after the failure of standardized treatment (3.8 vs 8.0 months).

Overall survival from the diagnosis of unresectable mCRC following curative resection was likewise longer for those who were administered regorafenib than for those who were not (18.9 vs 34.9 months).

In the study sample, the most common adverse event was any grade of hand-foot-skin reaction, observed in 69.4 percent of the participants; grade 3 of this adverse event was observed in 30.5 percent. This was followed by fatigue (41.6 percent), liver function abnormalities (38.9 percent), mucositis (36.1 percent), rashes (36.1 percent), diarrhoea (33.3 percent) and hyperbilirubinemia (27.7 percent).

Other adverse events included bleeding (5.6 percent), hypertension (16.6 percent), nausea (16.9 percent) and anorexia (22.2 percent).

There were four grade 4 adverse events: elevated aspartate transaminase (2.7 percent) and alanine transaminase (2.7 percent) levels, hypertension (2.7 percent), and hyperbilirubinemia (5.5 percent). No treatment-related deaths were reported.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.